| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | GSK2126458 | GDSC1000 | pan-cancer | AAC | -0.058 | 0.07 |
| mRNA | GMX-1778 | CTRPv2 | pan-cancer | AAC | -0.066 | 0.07 |
| mRNA | THZ-2-102-1 | GDSC1000 | pan-cancer | AAC | -0.054 | 0.08 |
| mRNA | Erlotinib | gCSI | pan-cancer | AAC | -0.099 | 0.08 |
| mRNA | Doxorubicin | GDSC1000 | pan-cancer | AAC | -0.063 | 0.08 |
| mRNA | doxorubicin:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.06 | 0.08 |
| mRNA | SGX-523 | CTRPv2 | pan-cancer | AAC | 0.067 | 0.08 |
| mRNA | Sorafenib | GDSC1000 | pan-cancer | AAC | -0.095 | 0.08 |
| mRNA | JQ-1 | GDSC1000 | pan-cancer | AAC | -0.057 | 0.08 |
| mRNA | RDEA119 | GDSC1000 | pan-cancer | AAC | -0.053 | 0.08 |